NASDAQ: PHAR - Pharming Group N.V.

Yield per half year: +26.96%
Sector: Healthcare

Share chart Pharming Group N.V.

Extended chart Simple chart
Financial Markets by TradingView

About

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.

more details
It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-12-23
ISIN US71716E1055
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.pharming.com
Цена ао 10.85
Change price per day: -3.59% (10.6001)
Change price per week: +12.31% (9.1)
Change price per month: +34.92% (7.575)
Change price per 3 month: +20.38% (8.4901)
Change price per half year: +26.96% (8.05)
Change price per year: -10.59% (11.43)
Change price per 3 year: +21.23% (8.43)
Change price per 5 year: 0% (10.22)
Change price per 10 year: 0% (10.22)
Change price per year to date: +32.38% (7.72)
All parameters

Underestimation

Title Value Grade
P/S 3.3 5
P/BV 3.7 5
P/E 58.02 2
EV/EBITDA -323.93 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -2.28 0
ROE, % -4.82 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -50.05 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 15.99 3
Yield Ebitda, % -88.27 0
Yield EPS, % -102.39 0
Total: 0.6
More

Institutions Volume Share, %
Silverberg Bernstein Capital Management LLC 17710 0.03
Morgan Stanley 2800 0



Head Job title Payment Year of birth
Dr. Sijmen de Vries M.B.A., M.D. President, CEO & Executive Director 1.44M 1959 (66 years)
Mr. Jeroen Wakkerman Chief Financial Officer N/A 1969 (56 years)
Ms. Mireille Sanders M.Sc. Chief Operations Officer N/A 1968 (57 years)
Susanne Embleton Investor Relations Manager N/A
Mr. Ruud Van Outersterp Chief Ethics & Compliance Officer N/A 1964 (61 year)
Dr. Anurag Relan M.D., MPH Chief Medical Officer N/A 1972 (53 years)
Mr. Stephen Toor Chief Commercial Officer & GM Americas N/A 1971 (54 years)
Dr. Alexander Breidenbach M.B.A. Chief Business Officer N/A 1964 (61 year)
Dr. Bruno M. L. Giannetti Consultant N/A 1952 (73 years)

Address: Netherlands, Leiden CR, Darwinweg 24 - open in Google maps, open in Yandex maps
Website: https://www.pharming.com